Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082966 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00082966: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00082966 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00082966, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
Interventions
- DRUG 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082966
The ClinicalTrials.gov registry entry for NCT00082966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 17-N-allylamino-17-demethoxygeldanamycin/bortezomib is the first listed.
NCT00082966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082966 about?
NCT00082966 is a clinical study titled "Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma". Phase II trial to study the effectiveness of bortezomib in treating patients who have relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00082966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00082966?
The interventions under investigation include: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib (DRUG).
Who is sponsoring clinical trial NCT00082966?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.